Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993663/29248/en/Anavex-Life-Sciences-to-Report-New-Long-Term-Oral-Blarcamesine-Phase-IIb-III-Alzheimer-s-Disease-Data-at-J-P-Morgan-2025-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    25 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/25/2986572/29248/en/Anavex-Life-Sciences-Announces-Acceptance-of-Peer-Reviewed-Manuscript-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-a-Reference-Alzheimer-s-Disease-Journal.html

    GLOBENEWSWIRE
    25 Nov 2024
    Share Share
    NANOBIOTIX to Attend Investor Conferences in November
    NANOBIOTIX to Attend Investor Conferences in November

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972317/0/en/NANOBIOTIX-to-Participate-in-Multiple-Investor-Conferences-in-November.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920900/29248/en/Anavex-Life-Sciences-Announces-Translational-Biomarker-Data-for-ANAVEX-2-73-blarcamesine-in-Fragile-X-Syndrome-Major-Cause-of-Autism-at-the-19th-NFXF-International-Fragile-X-Confer.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share